Dan Lou, Co-founder and Chairman Mr. Lou established Shenyang Sunshine, 3SBio’s predecessor and PRC operating subsidiary, in 1993 and served as President and Chief Engineer until 2003. From 1961 to 1993, Mr. Lou served in several positions in Shenhou Institute of Military Medicine, including assistant military doctor, military doctor, Deputy Director and Director of Department of Microbiology and Immunology. Currently, Mr. Lou also serves as an Executive Director at China Medicinal Biotech Association. Mr. Lou graduated from the Third Military Medical University in 1955.
	Dr. Jing Lou, Co-founder, Chief Executive Officer and Director Dr. Lou has served as Chief Executive Officer of Shenyang Sunshine, now 3SBio, since 2000. He joined Shenyang Sunshine as Director of Research and development in 1995. Prior to joining the company, Dr. Lou founded Lifegen, Inc., a Maryland Corporation and an investee company of Shenyang Sunshine, to optimize the manufacturing processes for EPIAO and TPIAO in the U.S. Dr. Lou completed his post-doctoral study at the U.S. National Institutes of Health in 1995. He received his Ph.D. in Molecular and Cell Biology in 1993 from Fordham University, where he researched interferon signal transduction of gene regulation, and received his medical doctor degree in 1985 from Shanghai 2nd Military Medical University.
	Bin Huang,Vice President of Human Resources and Director Mr. Huang has served as vice president in charge of human resources and legal matters since joining Shenyang Sunshine in 1993. Before that he acted as office manager for Shenyang Army Medical Research Center from 1976 to 1993. He received his MBA from Qinghua University in 2002 and a bachelor’s degree in engineering from the Northeast University in 1987.
	David Chen,Executive Vice President and Chief Operating Officer Mr. Chen joined 3SBio in 2007. He is responsible for pursuing strategic business opportunities and external alliances and partnerships with biotechnology and pharmaceutical companies in major markets. Mr. Chen is a former medical doctor and has held various management positions in multinational pharmaceutical companies in the US, including GlaxoSmithKline and Eli Lilly & Company.  He received his MBA degree in from Darden Business School of University of Virginia in 1998 and an MD degree in from First Military Medical College in 1989.
	Bo Tan, Chief Financial Officer Bo Tan joined 3SBio as the CFO in February 2009. He has extensive experience within the financial and pharmaceutical industries, having worked across private equity, equity research and commercial practice. Previously, he served as the Executive Director and a member of Investment Committee for Bohai Industrial Fund Management Company, a private equity fund in China.  Earlier in his career, he spent six years in the pharmaceutical industry with Eli Lilly & Company and EMD Pharmaceuticals, Inc in North America and went on to serve as a China healthcare and consumer analyst at Lehman Brothers Asia and Macquarie Securities in Hong Kong. He received his MBA degree from Thunderbird School of International Management, an MA degree in economics from the University of Connecticut and a BA degree in economics from Renmin University of China.  Mr. Tan is also a CFA (Chartered Financial Analyst).
	Dr. Yingfei Wei, Chief Scientific Officer and Vice President for Business Development Dr. Wei joined 3SBio in August 2006. She has over fifteen years of research and development experience in the biotechnology and pharmaceutical sectors. Before joining 3SBio, Dr. Wei was the Co-founder, President and Chief Executive Officer of Elixirin Corporation from 2004 to 2005, responsible for overseeing contract research, manufacturing, regulatory approvals and marketing of anti-aging products in the U.S. and China. Prior to that, she was Director of Biotechnology Research at Bayer HealthCare Global from 1998 to 2004 and group leader at the discovery research department of Human Genome Sciences Inc. from 1993 to 1998. Dr. Wei is the inventor of 37 patents and has authored several publications, primarily in the areas of protein and antibody drug discovery and genomics. Dr. Wei was a postdoctoral fellow at Harvard University’s School of Public Health in 1993. She received her Ph.D. in biochemistry from the University of California in 1990 and a bachelor’s degree in biochemistry from Beijing University in 1983.
	Dongmei Su, Chief Technology Officer Ms. Su is responsible for research and development and manufacturing process engineering. She is the named co-inventor for four of our patents. Ms. Su joined Shenyang Sunshine, now 3SBio, in 1993, and has served as Director of Research and Development and Manufacturing since 1997. She received her bachelor’s degree in biochemical engineering from Jilin University in 1992, and her master’s degree in microbiology and pharmacology from Shenyang Pharmaceutical University in 2001.
	Ke Li, Corporate Secretary Mr. Li is responsible for all corporate and government regulatory matters. Mr. Li has served in his current role since 1996. He joined the company in 1993 and held various administrative positions at Shenyang Sunshine before he was appointed Corporate Secretary. Mr. Li received his MBA from Liaoning University in 2001 and his bachelor’s degree in engineering from Jilin University in 1988.